This is of special interest since the inhibition of BCR-related kinases that also participate in the CXCR4 signaling is showing promising results in preliminary clinical trials in patients with CLL [43]–[45]. The gene discussed is BCR; the disease is B-cell chronic lymphocytic leukemia.